, Volume 21, Issue 1, pp 79–90

Green-lipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: therapeutic efficacy and effects on gastrointestinal microbiota profiles

  • Samantha Coulson
  • Henry Butt
  • Phillip Vecchio
  • Helen Gramotnev
  • Luis Vitetta
Research Article



To investigate how changes in the gastrointestinal tract (GIT) microbiota profile may influence nutraceutical efficacy in osteoarthritis (OA) and allow the formulation of a hypothesis that explains in part the inconsistent and contentious findings from OA clinical studies with green-lipped mussel (GLM) and glucosamine.


A non-blinded randomised clinical trial was conducted with 38 subjects diagnosed with knee OA. Each participant received either 3,000 mg/day of a whole GLM extract or 3,000 mg/day of glucosamine sulphate (GS), p.o. for 12 weeks. Faecal microbial analyses were carried out after collecting stools at T0 and T12 weeks. Additional pharmacometric measures were obtained from changes in arthritic scores in the Western Ontario McMaster Universities Arthritis Index (WOMAC) and the Lequesne algofunctional indices and the Gastrointestinal Symptom Rating Scale (GSRS). An intention-to-treat analysis was employed and participant data collected at T0, T6 and T12 weeks.


There were no statistically significant changes in bacterial growth patterns determined by the Wilcoxon test. In both groups there was a trend towards a decrease in Clostridium and Staphylococcus species and increase in Lactobacillus, Streptococcus and Eubacterium species. In the GLM group Bifidobacterium tended to increase and Enterococcus and yeast species to decrease. The GS-treated group demonstrated a trend towards a decrease in Bacteroides and an increase in yeasts and Coliforms species, most notably Escherichia coli. We further confirm significant improvement (p < 0.05) in all OA outcome measures from T0 to T12 weeks for both the GLM and GS groups. The GSRS scores indicated that GIT function significantly improved over the 12 weeks duration with GLM and GS supplementation.


Both GLM and GS reduced OA symptoms and non-significantly altered the gut microbiota profile from baseline. Changes in the microbiota profiles occurred in both treatment groups; the most notable being a reduction in the Clostridia sp. This study suggests that nutritional supplements such as GLM and GS may regulate some of the metabolic and immunological activities of the GIT microbiota. The decrease in Clostridia, a potent modulator of colonic Th17 and CD4+ regulatory T cells, was consistent with a decrease in inflammation; improved GSRS scores and OA symptoms for these OA participants. The GIT microbiota may be important factor in the first-pass metabolism of these nutraceuticals.


Gastrointestinal tract Microbiota Green-lipped mussel Perna canaliculus Glucosamine Osteoarthritis Clostridia sp. 


  1. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F (2002) Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci 5(2):181–184PubMedGoogle Scholar
  2. Altman R, Ach E, Bloch D et al (1986) Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthr Rheum 29(8):1039–1049CrossRefGoogle Scholar
  3. Atarashi K, Tanoue T, Shima T et al (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331(6015):337–341PubMedCrossRefGoogle Scholar
  4. Barnes MJ, Powrie F (2011) Immunology. The gut’s Clostridium cocktail. Science 331(6015):289–290PubMedCrossRefGoogle Scholar
  5. Bellamy N (2002) WOMAC: a 20-year experiential review of a patient-centred self-reported health status questionnaire. J Rheumatol 29(12):2473–2476PubMedGoogle Scholar
  6. Bellamy N, Buchanan W, Goldsmith CH et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMedGoogle Scholar
  7. Bjordal J, Ljunggren AE, Klovning A, Slordal L (2004) Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee: meta-analysis of randomised placebo controlled trials. Br Med J 329(7478):1317–1322CrossRefGoogle Scholar
  8. Brien S, Prescott P, Coghlan B et al (2008) Systematic review of the nutritional supplement Perna Canaliculus (green-lipped mussel) in the treatment of osteoarthritis. Q J Med 101(3):167–179CrossRefGoogle Scholar
  9. Chitturi S, George J (2002) Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 22(2):169–183PubMedCrossRefGoogle Scholar
  10. Chong V, Wang C (2008) Higher prevalence of gastrointestinal symptoms among patients with rheumatic disorders. Singap Med J 49(5):419–424Google Scholar
  11. Coulson S, Vecchio P, Gramotnev H, Vitetta L (2012) Green-lipped mussel (Perna canaliculus) extract efficacy in knee osteoarthritis and improvement in gastrointestinal dysfunction: a pilot study. Inflammopharmacology 20(2):71–76PubMedCrossRefGoogle Scholar
  12. Egert M, de Graaf AA, Smidt H et al (2006) Beyond diversity: functional microbiomics of the human colon. Trends Microbiol 14:86–91PubMedCrossRefGoogle Scholar
  13. Ehrlich G (2003) Global treatment of osteoarthritis. Inflammopharmacology 11(4–6):333–336PubMedCrossRefGoogle Scholar
  14. Ernst E (1998) Usage of complementary therapies in rheumatology: a systematic review. Clin Rheumatol 17:301–305PubMedCrossRefGoogle Scholar
  15. Foley S, Stolarczyk E, Mouni F et al (2008) Characterisation of glutamine fructose-6-phosphate amidotransferase (EC and N-acetylglucosamine metabolism in Bifidobacterium. Arch Microbiol 189(2):157–167PubMedCrossRefGoogle Scholar
  16. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E et al (2009) The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31(4):677–689PubMedCrossRefGoogle Scholar
  17. Garcia Rodriguez LA, Hernandez-Diaz S (2001) Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12(5):570–576PubMedCrossRefGoogle Scholar
  18. Gillett R, Norrell A (2011) Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician 83(6):711–716PubMedGoogle Scholar
  19. Guarner F, Malagelada JR (2003) Gut flora in health and disease. Lancet 361(9356):512–519PubMedCrossRefGoogle Scholar
  20. Holzapfel W, Haberer P, Snel J et al (1998) Overview of gut flora and probiotics. Int J Food Microbiol 41:85–101PubMedCrossRefGoogle Scholar
  21. Kelly D, Conway S, Aminov R (2005) Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol 26(6):326–333PubMedCrossRefGoogle Scholar
  22. Koser S, Tribby I, Stuedell J (1961) Glucosamine utilization by some lactic acid bacteria. J Infect Dis 108:324–332PubMedCrossRefGoogle Scholar
  23. Laparra JM, Sanz Y (2010) Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61(3):219–225PubMedCrossRefGoogle Scholar
  24. Lequesne MG, Mery C, Samson M, Gerard P (1987) Indexes of severity for osteoarthritis of the hip and knee validation-value in comparison with other assessment tests. Scand J Rheumatol 65:85–89CrossRefGoogle Scholar
  25. Lutwak-Mann C (1941) Enzymatic decomposition of amino-sugars. Biochem J 35(5):610–626PubMedGoogle Scholar
  26. Reginster JY (2002) The prevalence and burden of arthritis. Rheumatology (Oxford) 41(Supp 1):3–6CrossRefGoogle Scholar
  27. Rutjes A, Nüesch E, Reichenbach S, Jüni P (2008) S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 4:CD007321Google Scholar
  28. Smith K, McCoy KD, Macpherson AJ (2007) Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 19(2):59–69PubMedCrossRefGoogle Scholar
  29. Stepankova R, Powrie F, Kofronova O et al (2007) Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis 13(10):1202–1211PubMedCrossRefGoogle Scholar
  30. Svedlund J, Sjodin I, Dotevall G (1988) GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33:129–134PubMedCrossRefGoogle Scholar
  31. Tana C, Umesaki Y, Imaoka A et al (2010) Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22(5):512–519, e114–e115Google Scholar
  32. Thrupp L (1980) Susceptibility testing of antibiotics in liquid media. In: Lorian V (ed) Antibiotics in laboratory medicine, chap 4. Williams & Wilkins pub, Baltimore, pp 73–113Google Scholar
  33. Towheed T, Maxwell L, Anastassiades TP et al (2005) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2:CD002946Google Scholar
  34. Tucker G, Adams R, Wilson D (2010) New Australian population scoring coefficients for the old version of the SF-36 and SF-12 health status questionnaires. Qual Life Res 19:1069–1076PubMedCrossRefGoogle Scholar
  35. Ulbricht C, Chao W, Costa D et al (2009) An evidence-based systematic review of green-lipped mussel (Perna canaliculus) by the Natural Standard Research Collaboration. J Diet Suppl 6(1):54–90PubMedCrossRefGoogle Scholar
  36. Umesaki Y, Setoyama H, Matsumoto S et al (1999) Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun 67:3504–3511PubMedGoogle Scholar
  37. Vitetta L, Briskey D, Hayes E et al (2012) A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics. Inflammopharmacology (Epub ahead of print)Google Scholar
  38. Wandel S, Juni P, Tendal B et al (2010) Effects of glucosamine, chondroitin or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341:c4675PubMedCrossRefGoogle Scholar
  39. Ware J, Kosinski M, Keller S (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–233PubMedCrossRefGoogle Scholar
  40. Willis A (2007) Anaerobic culture methods, in anaerobic microbiology: a practical approach. IRL Press at Oxford University Press, OxfordGoogle Scholar
  41. Wolfe J, Nakada H (1956) Glucosamine degradation by Escherichia coli. II. The isomeric conversion of glucosamine 6-PO4 to fructose 6-PO4 and ammonia. Arch Biochem Biophys 64(2):489–497PubMedCrossRefGoogle Scholar
  42. Wolfe J, Morita R, Nakada H (1956) Glucosamine degradation by Escherichia coli, I. Observations with resting cells and dry-cell preparations. Arch Biochem Biophys 64:480–488PubMedCrossRefGoogle Scholar
  43. Wolfe F, Kong S, Watson D (2000) Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol 27(6):1373–1378PubMedGoogle Scholar
  44. Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81(9):646–656PubMedGoogle Scholar
  45. Wu H, Ivanov I, Darce J et al (2010) Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32(6):815–827PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  • Samantha Coulson
    • 1
  • Henry Butt
    • 2
  • Phillip Vecchio
    • 3
  • Helen Gramotnev
    • 1
  • Luis Vitetta
    • 1
  1. 1.The Centre for Integrative Clinical and Molecular MedicineThe University of Queensland, School of Medicine, Princess Alexandra HospitalWoolloongabbaAustralia
  2. 2.Bioscreen, Bio21Molecular Science and Biotechnology Institute, University of MelbourneMelbourneAustralia
  3. 3.Department of RheumatologyPrincess Alexandra HospitalBrisbaneAustralia

Personalised recommendations